다음 MAP메이트™는 통합될 수 없습니다: -다른 분석 완충용액이 필요한 MAP메이트™. -인산 특이성 및 총 MAP메이트™ 조합, 예: 총 GSK3β 및 GSK3β(Ser 9). -PanTyr 및 자리 특이성 MAP메이트™, 예: Phospho-EGF 수용체 및 phospho-STAT1(Tyr701). -단일 표적(Akt, STAT3)를 위한 1개 이상의 1 phospho-MAP메이트™. - GAPDH 및 β-Tubulin은 panTyr를 포함하는 키트 또는 MAP메이트™와 통합될 수 없습니다.
Custom Premix Selecting "Custom Premix" option means that all of the beads you have chosen will be premixed in manufacturing before the kit is sent to you.
Catalogue Number
Ordering Description
Qty/Pack
List
이 제품은 즐겨찾기에 저장되었습니다.
종
패널 유형
선택하신 키트
수량
카탈로그 번호
주문 설명
포장 단위
기재 가격
96-Well Plate
수량
카탈로그 번호
주문 설명
포장 단위
기재 가격
다른 시약 추가 (MAP메이트 사용을 위해 완충용액과 검출 키트가 필요함)
수량
카탈로그 번호
주문 설명
포장 단위
기재 가격
48-602MAG
Buffer Detection Kit for Magnetic Beads
1 Kit
공간 절약 옵션 다수의 키트를 구매하시는 고객은 고용량 저장을 위해 키트 포장을 제거하고 비닐백에 담긴 멀티플레스 분석 구성품을 받아 저장 공간을 절약하도록 선택할 수 있습니다.
이 제품은 즐겨찾기에 저장되었습니다.
해당 제품은 고객님의 카트에 추가되었습니다.
이제 다른 키트를 사용자 지정하거나, 사전 혼합된 키트를 선택하거나, 결재하거나 또는 주문 도구를 종료할 수 있습니다.
114825
Sigma-AldrichAdapalene - CAS 106685-40-9 - Calbiochem
A cell-permeable naphthoic acid compound that exhibits selective affinity and agonistic potency toward RARβ and RARγ over RARα.
More>>A cell-permeable naphthoic acid compound that exhibits selective affinity and agonistic potency toward RARβ and RARγ over RARα. Less<<
Adapalene - CAS 106685-40-9 - Calbiochem MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.
A cell-permeable naphthoic acid compound that exhibits selective affinity and agonistic potency toward RARβ and RARγ over RARα (Kd = 34, 130, and 1100 nM, respectively; AC50 = 2.3, 9.3, and 22 nM, respectively, in COS-7-based reporter assays) without appreciable affinity toward cytosolic retinoic acid binding proteins CRABP I/II (Kd >> 1 µM) or detectable activity toward RXRα (AC50 > 1 µM). The biological activity and pharmaceutical efficacy of ADA are generally shown to be superior to those of ATRA/Tretinoin (Cat. No. 554720) both in vitro and in vivo.
Catalogue Number
114825
Brand Family
Calbiochem®
Synonyms
CD271, RAR Agonist V, ADA, Differin, 6-(3-(1-Adamantyl)-4-methoxyphenyl)-2-naphthoic acid, CD 271
References
References
Irby, C.E., et al. 2008. J. Adolesc. Health43, 421. Ocker, M., et al. 2003. Int. J. Cancer107, 453. Kim, M.J., et al. 2000. J. Invest. Dermatol.114, 349. Shroot, B., et al. 1997. J. Am. Acad. Dermatol.36, S96.
Adapalene - CAS 106685-40-9 - Calbiochem Certificates of Analysis
Title
Lot Number
114825
References
참고문헌 보기
Irby, C.E., et al. 2008. J. Adolesc. Health43, 421. Ocker, M., et al. 2003. Int. J. Cancer107, 453. Kim, M.J., et al. 2000. J. Invest. Dermatol.114, 349. Shroot, B., et al. 1997. J. Am. Acad. Dermatol.36, S96.
Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.
Revision
01-September-2010 RFH
Synonyms
CD271, RAR Agonist V, ADA, Differin, 6-(3-(1-Adamantyl)-4-methoxyphenyl)-2-naphthoic acid, CD 271
Description
A cell-permeable naphthoic acid compound that exhibits selective affinity and agonistic potency toward RARβ and RARγ over RARα (Kd = 34, 130, and 1100 nM, respectively; AC50 = 2.3, 9.3, and 22 nM, respectively, in COS-7-based reporter assays) without appreciable affinity toward cytosolic retinoic acid binding proteins CRABP I/II (Kd >> 1 µM) or detectable activity toward RXRα (AC50 > 1 µM). The biological activity and pharmaceutical efficacy of ADA are generally shown to be superior to those of ATRA/Tretinoin (Cat. No. 554720) both in vitro and in vivo.
Form
White solid
Intert gas (Yes/No)
Packaged under inert gas
CAS number
106685-40-9
Chemical formula
C₂₈H₂₈O₃
Structure formula
Purity
≥97% by HPLC
Solubility
DMSO (12 mg/ml)
Storage
Protect from light
+2°C to +8°C
Do Not Freeze
Ok to freeze
Special Instructions
Following initial thaw, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Toxicity
Standard Handling
References
Irby, C.E., et al. 2008. J. Adolesc. Health43, 421. Ocker, M., et al. 2003. Int. J. Cancer107, 453. Kim, M.J., et al. 2000. J. Invest. Dermatol.114, 349. Shroot, B., et al. 1997. J. Am. Acad. Dermatol.36, S96.
